Proceedings of the Tenth International Conference of Drug Regulatory Authorities (ICDRA) - Hong Kong, China, 24 - 27 June 2002
(2002; 166 pages) View the PDF document
Table of Contents
View the documentAbbreviations and acronyms used in this report
Open this folder and view contentsOpening ceremony
Close this folderHerbal medicines
View the documentCurrent status of traditional Chinese medicines in China
View the documentRegulation of traditional Chinese medicines in Hong Kong, China
View the documentProposed regulations for natural health products in Canada
View the documentHow regulation of herbal medicines was established in Thailand
View the documentHerbal medicine in the Islamic Republic of Iran
View the documentTraditional herbal medicines: an update on European Union activities
View the documentRegulation of herbal medicines in Ghana
View the documentRecommendations
Open this folder and view contentsKeynote address
Open this folder and view contentsSafety of blood-derived products
Open this folder and view contentsAntimicrobial resistance - new initiatives
Open this folder and view contentsHarmonization I
Open this folder and view contentsHarmonization II
Open this folder and view contentsProtection of trial subjects in clinical trials
Open this folder and view contentsRegulating biotechnology products
Open this folder and view contentsRegulatory challenges: health sector reform and drug regulatory capacity
Open this folder and view contentsAccess to drugs and vaccines I
Open this folder and view contentsAccess to drugs and vaccines II
Open this folder and view contentsCounterfeit pharmaceutical products
Open this folder and view contentsHomoeopathy
Open this folder and view contentsSafety monitoring
Open this folder and view contentsE-Commerce
Open this folder and view contentsCurrent topics
Open this folder and view contentsRegulatory challenges of new technologies
View the documentList of participants
View the documentBack cover
 

Recommendations

1. Member States, together with WHO, should define criteria and standards for herbal medicines, health or functional foods, and dietary supplements. WHO should continue to develop guidelines on the assessment of safety, efficacy and quality control of herbal medicinal products and herbal combinations.

2. The safe use of herbal medicines is a major concern for governments and consumers. WHO should provide guidance to countries wishing to establish safety monitoring systems or to expand existing systems to monitor and report adverse reactions to herbal medicines. Member States should strengthen their postmarketing surveillance systems for herbal medicines. Such systems should involve health care providers, consumers and manufacturers.

3. WHO should support countries in developing sources of information on herbal medicines while facilitating informationsharing among countries. WHO should provide guidance to governments and nongovernmental organizations (NGOs) on how to develop information and educational programmes on the proper use of herbal medicines for the public.

4. WHO should provide guidance for governments and NGOs on training of traditional medicine providers, and promote communication with other health workers.

5. Member States should seek funds to support research on herbal medicines.

6. Progress should be reported back to the ICDRA.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 7, 2014